Skip to content
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP

Immunocore Holdings PLC IMCR

5 fiscal years on record · GBP · FY2022 reported · SEC filings only
£143.7M
▲ 442.0% YoY
£-41.2M
£-27.7M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

The Company has commercially launched KIMMTRAK, its lead product, in 30 countries, including the United States, Germany and France, and the product is approved in 39 countries. In 2022, it received approval for KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma from the FDA, the European Commission and other health authorities. KIMMTRAK is manufactured at facilities located in Denmark and Germany, with final packaging completed in the Netherlands. It currently leverages its platform within three therapeutic areas: cancer, infectious diseases, and autoimmune diseases. As of December 31, 2025, it had 524 full-time employees who worked primarily in the United Kingdom and the United States. It was originally incorporated under the laws of England and Wales in December 2007 as a private company with limited liability called Immunocore Limited. On February 1, 2021, Immunocore Holdings Limited re-registered as a public limited company and was renamed Immunocore Holdings plc.

Written from the business description in Immunocore Holdings plc's annual report to the U.S. Securities and Exchange Commission, filed 25 February 2026. Every sentence was checked against that document before publication.

Growth

GBP 143.7M
Revenue, FY2022 · full 5-year series below
Revenue £M Net income £M
FY2022 · Revenue 143.7 · Net income -41.2
100M200M-50M-100M
201820212022
Compound annual growth
+77.6%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−29 cents
lost on every revenue dollar
Operating margin Net margin
FY2022 · Operating -27.6% · Net -28.7%
-200%-400%
201820202022
ROE
FY2022 · ROE -18.3%
-100%-200%
201820202022
Three returns, three denominators.

Each GBP of equity lost 18 cents this year.

Cash & shareholders

·
returned in FY2022 · dividends + net buybacks
Free cash flow £M
FY2022 · FCF -27.7
-50M-100M
201820202022

Total assetsGBP 435.5M
CashGBP 332.5M
Gross debtGBP 39.5M
Net debtGBP -293.0M
Current ratio4.72×

Net debt stands at -105% of equity.

The 5-year record

5 fiscal years
Every figure from documents filed with the SEC · GBP

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
IMCR, 5-year financial record
Metric 20222021202020192018
Revenue £B0.10.00.00.00.0
Operating income £B−0.0−0.1−0.1−0.1−0.1
EBITDA £B◌◌◌◌◌
Income tax £B−0.0−0.0−0.0−0.0−0.0
Net income £B−0.0−0.1−0.1−0.1−0.1
Free cash flow £B−0.0−0.1−0.1−0.1−0.0
EPS, diluted £−0.90−3.10−2.79−4.66◌
Dividend / sh £◌◌0.01◌◌
Payout %◌◌◌◌—
ROE %−18.3−115.9−211.3−291.3−126.6
Shares out B◌0.000.000.000.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 4 failures in 17 reconciliationsAUDITED

Reconciled in 1 of the 5 fiscal years we could check. 24 checks were skipped: the balance sheet is not tagged before 2019. 13 checks were skipped: cost of revenue is not tagged before 2020. 12 checks were skipped: EPS is not tagged before 2019.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency4 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inoutside the United States — SEC code X0
Fiscal year endsDecember 31
Data on record since2018

Share this section

Download image